CARDIAWAVE


Associated tags: Certification, RHU, Cardiovascular disease, Mortality, EN, Cardiology, Biotechnology, Health, Medical Devices, Pharmaceutical industry, Patient, CARDIAWAVE, Safety, Medical imaging, Medical device, Trial of the century, CE, FIH, Aortic stenosis, Clinical Trials, AP-HP, Other Health, AORTIC STENOSIS

Locations: NY, NEW YORK, EUROPE, UNITED STATES, NORTH AMERICA, FRANCE, GEORGIA, PARIS

Cardiawave appoints Olivier Pierron as its Chief Executive Officer

Retrieved on: 
Tuesday, April 16, 2024
Cardiology, Biotechnology, Pharmaceutical, Medical Supplies, Health, Medical Devices, Clinical Trials, Other Health, Tech, CE marking, FIH, Research, France Biotech, IPO, Patient, Acquisition, Multimedia, Organization, Ultrasound, Pharmaceutical industry

Cardiawave SA, a French Medtech company that has developed an innovative Non-Invasive Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis, is delighted to announce the appointment of Olivier Pierron as its new Chief Executive Officer.

Key Points: 
  • Cardiawave SA, a French Medtech company that has developed an innovative Non-Invasive Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis, is delighted to announce the appointment of Olivier Pierron as its new Chief Executive Officer.
  • View the full release here: https://www.businesswire.com/news/home/20240416024431/en/
    Before joining Cardiawave, Olivier Pierron held executive roles at some well-known companies in the sector, showing his capabilities as a manager and innovator in organizations at various stages of maturity.
  • His international experience, combined with his involvement in development, acquisition and IPO transactions, makes him a sound strategic choice to lead Cardiawave towards new horizons.
  • Olivier Pierron, Cardiawave’s new CEO, said: “The approach developed by Cardiawave is unique and complements the existing range of cardiology treatments.

Cardiawave is presenting the 30-day follow-up results from its “Valvosoft® Pivotal Study” on the treatment of severe symptomatic aortic valve stenosis

Retrieved on: 
Friday, April 5, 2024
Medical Devices, Health, Clinical Trials, Radiology, Cardiology, Biotechnology, Science, FIM, Patient, Journal, Research, Quality of life, American College, Calendar

Cardiawave SA, a French medtech company that has developed an innovative Non-Invasive focused Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis, will present the 30-day follow-up results for 60 patients enrolled in its European pivotal study to the 73rd annual conference of the American College of Cardiology in Atlanta, Georgia.

Key Points: 
  • Cardiawave SA, a French medtech company that has developed an innovative Non-Invasive focused Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis, will present the 30-day follow-up results for 60 patients enrolled in its European pivotal study to the 73rd annual conference of the American College of Cardiology in Atlanta, Georgia.
  • This is a leading event in the cardiovascular medicine calendar, which brings together specialists from around the world to discuss the latest advances, research results and clinical innovations in the field of cardiology.
  • Prof. Eric Van Belle, cardiologist at Lille University Hospital, one of the principal investigators for the European pivotal study, commented: “I’m very proud to present the excellent results obtained using Cardiawave’s NIUT device to treat patients with severe symptomatic aortic valve stenosis, leading to a significant improvement in their condition and a better quality of life.
  • Time and date: April 8, 2024 - 9:32 a.m.–9:42 a.m. EDT
    The results of the Cardiawave First-in-Human “Valvosoft® FIM Study” were published in The Lancet in November 2023:

Cardiawave Announces the Publication in The Lancet of First-In-Human Clinical Studies Results With 40 Aortic Stenosis Patients Treated With Its Innovative Non-invasive Ultrasound Therapy (NIUT)

Retrieved on: 
Wednesday, November 15, 2023
Research, Medical Devices, Clinical Trials, Cardiology, Biotechnology, Other Health, Radiology, Health, Science, FACP, Food, Treatment, Medtech, FAHA, AP-HP, FACC, CAS, Mortality, FCCP, Patient, FIH, Ultrasound, FDA, CE, MD, Trial of the century, FESC, Doctor of Philosophy, Quality of life, Medical device, Pharmaceutical industry, Lancet

The patients were treated with Cardiawave’s NIUT investigational device in one session.

Key Points: 
  • The patients were treated with Cardiawave’s NIUT investigational device in one session.
  • “Clinically, the patients experienced a considerable improvement in their clinical status suggesting a better quality of life.
  • These early findings can represent a change in the paradigm of CAS treatment especially for patients who have no other options.
  • In July 2023, Cardiawave successfully completed the patient enrolment with no procedure or device-related mortality up to 30 days.

Cardiawave Granted 3 New Patents Extending Its Intellectual Property Protection for Its Technology in the United States

Retrieved on: 
Monday, February 13, 2023
Cardiology, Data Management, Biotechnology, Technology, Manufacturing, Other Health, Health, Other Technology, Medical Devices, Other Manufacturing, Mobile, Wireless, Deep vein thrombosis, Cardiovascular disease, CE, Hospice, Trial of the century, Patient, TCT, Safety, Patent, Medicare, United States patent law, TAVR, Multimedia, Aortic stenosis, Ageing, Medical device, Medical imaging, Pharmaceutical industry

The second U.S. Patent protects the technology and the means to detect and monitor with ultrasound imaging the cavitation bubbles which create the therapeutic effect generated by the emission of focused ultrasound.

Key Points: 
  • The second U.S. Patent protects the technology and the means to detect and monitor with ultrasound imaging the cavitation bubbles which create the therapeutic effect generated by the emission of focused ultrasound.
  • The third U.S. Patent protects the entire apparatus for treating deep vein thrombosis with focused ultrasounds.
  • Cardiawave is currently carrying out a pivotal clinical study in Europe, in order to obtain the CE marking and launch the commercialization of its device.
  • "We are thrilled to receive these new patents for our innovative solution to treat non-invasively aortic stenosis and other cardiovascular diseases," said Benjamin BERTRAND, CEO of Cardiawave.

Cardiawave Announces the Success of Its Clinical Trial to Treat Aortic Stenosis Using VALVOSOFT®, Its Disruptive, Non-Invasive, Ultrasound Treatment

Retrieved on: 
Monday, March 14, 2022
Medical Devices, Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Laboratoires Servier, Mortality, Cardiovascular disease, Technology, Patient, Sudden death, Heart failure, Valvular heart disease, Stenosis, Hospital, Protocol, FIH, Risk, Aortic stenosis, AP-HP, Safety, MRI, Brain, Stroke, CEO, TAVI, Magnetic resonance imaging, Certification, RHU, Electricity, Robotics, Percutaneous aortic valve replacement, Software, Aortic valve, Pathology, Medical imaging, Pharmaceutical industry, VALVOSOFT®, AORTIC STENOSIS, CARDIAWAVE, VALVOSOFT®, AORTIC STENOSIS, CARDIAWAVE

VALVOSOFT provided a sustained repair to the aortic vavlve for up to 12 months post treatment.

Key Points: 
  • VALVOSOFT provided a sustained repair to the aortic vavlve for up to 12 months post treatment.
  • This represents a new treatment solution for aortic stenosis, over and above aortic valve replacement from which only a small minority of patients can benefit.
  • This non-invasive treatment of aortic stenosis combines therapeutic ultrasound, robotics and ultrasound imaging.
  • Aortic stenosis is a degenerative and potentially life-threatening condition, caused by calcium buildup which prevents the aortic valve from fully opening.